HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Islet Cell Adenoma (Islet Cell Tumors)

Subscribe to New Research on Islet Cell Adenoma

A benign tumor of the pancreatic ISLET CELLS. Usually it involves the INSULIN-producing PANCREATIC BETA CELLS, as in INSULINOMA, resulting in HYPERINSULINISM.

Also Known As:

Islet Cell Tumors; Adenoma, Islet Cell; Island Cell Tumor; Adenomas, Islet Cell; Island Cell Tumors; Islet Cell Adenomas; Tumor, Island Cell; Tumor, Islet Cell; Tumors, Island Cell; Tumors, Islet Cell; Islet Cell Tumor; Nesidioblastoma

Networked: 455 relevant articles (14 outcomes, 42 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Neoplasms (Cancer)
2.	Carcinoid Tumor (Carcinoid)
3.	Neoplasm Metastasis (Metastasis)
4.	Adenocarcinoma
5.	Hyperplasia

Experts

1.	Fukuda, Izumi: 4 articles (01/2015 - 08/2006)
2.	Fendrich, Volker: 3 articles (01/2014 - 03/2011)
3.	Bartsch, Detlef K: 3 articles (01/2014 - 03/2011)
4.	Waldmann, Jens: 3 articles (01/2014 - 03/2011)
5.	Imamura, Masayuki: 3 articles (12/2005 - 01/2002)
6.	Lauth, Matthias: 2 articles (01/2014 - 03/2011)
7.	Slater, Emily P: 2 articles (01/2012 - 03/2011)
8.	Rehm, Johannes: 2 articles (01/2012 - 03/2011)
9.	Buchholz, Malte: 2 articles (01/2012 - 03/2011)
10.	Hizuka, Naomi: 2 articles (01/2012 - 08/2006)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Islet Cell Adenoma:

1.	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 07/01/1993 - "The results of visualization of the islet cell tumors of 25 patients after intravenous administration of two isotope-labeled somatostatin analogs (123I-Tyr3-octreotide and 111In-octreotide) are described. " 07/01/1993 - "Use of isotope-labeled somatostatin analogs for visualization of islet cell tumors." 03/01/1978 - "Effect of somatostatin in the Syrian hamster bearing a transplantable islet-cell tumor." 04/01/1993 - "Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors." 09/01/1992 - "We also describe the visualization, using intravenous (IV) administration of two isotope-labeled somatostatin analogues (123I-Tyr3-octreotide and 111In-DTPA-octreotide) of islet-cell tumors in 25 patients and carcinoids in 39 patients. "
2.	Streptozocin (Streptozotocin)FDA Link 03/01/1990 - "Streptozotocin (STZ) is a monofunctional nitrosourea employed in the treatment of patients with islet cell tumors. " 10/01/1989 - "Liver, kidney and islet cell tumors in spontaneously hypertensive and normotensive rats treated neonatally with streptozotocin." 06/01/1982 - "We describe a patient with metastatic islet cell tumor of the pancreas who was treated with 16 weekly courses of 1 g/m2 of streptozotocin without marked change in renal function. " 08/01/1981 - "These results suggest that a small dose of streptozotocin produces two types of islet cell tumors. " 06/01/1971 - "[Therapy of metastasizing islet cell tumor with streptozotocin]."
3.	GastrinsIBA 01/01/2013 - "Gastrin is expressed in the embryonic pancreas and is common in islet cell tumors, but the lineage and regulators of pancreatic gastrin(+) cells are not known. " 11/01/1996 - "A gastrin-producing islet cell tumor of the pancreatic head was also present. " 01/01/1980 - "It has now been well established that the ulcerogenic syndrome associated with non-beta islet cell tumors of the pancreas is due to excess gastrin release and consequent marked gastric acid hypersecretion. " 06/01/1974 - "Letter: Gastrin and islet-cell tumors." 12/01/1989 - "No patient with ZES and MEN I was cured of ZES despite the fact that islet cell tumor was removed from the region of the gastrin gradient in five of six patients. "
4.	Fluorouracil (Carac)FDA LinkGeneric 08/01/1994 - "5-Fluorouracil (5-FU) has shown modest single-agent activity in patients with carcinoid or islet cell tumors. " 08/01/1994 - "A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors." 11/01/1998 - "In the clinical diagnostic arena: the World Health Organization established a standard nomenclature for intraductal papillary mucinous neoplasms, mucinous cystic tumors, intraductal mucinous hyperplasias, and solid pseudopapillary tumors; focal glandular differentiation may be commonly identified within pancreatic endocrine neoplasms (islet cell tumors) while not necessarily implying an unfavorable prognosis typical of ductal adenocarcinomas; positron emission tomography scanning may be used for evaluation of early tumor response to novel chemotherapeutic regimens; helical computed tomography (CT) is the state of the art in preoperative imaging for pancreatic cancer; neoadjuvant 5-fluorouracil (5-FU)-based chemoradiation in 39 "resectable" patients provided a median survival of 19 months, actuarial 4-year survival of 19%, and improved local tumor control; gemcitabine has shown promise in alleviating tumor-related symptoms with a significantly better "clinical benefit response" than single agent 5-FU (23.8 vs. 4.8%, p = 0.0022) based on change in pain intensity, daily analgesic consumption, performance status, and weight; a significant survival advantage was demonstrated in patients treated with conventional therapies whose tumors expressed p21WAF-1, an important inhibitor of cell cycle progression and downstream molecule of p53 and TGF-beta; a p21-adenovirus (rAD-p21) gene therapy resulted in significant growth inhibition of pancreatic cancer cell lines in tissue culture, and development of a successful SCID mouse-human pancreatic adenocarcinoma xenograft model provided an animal model for preclinical trials of rAD-p21."
5.	HormonesIBA 03/01/2012 - "Commonly referred to as islet cell tumors, PanNETs are classified as functional or nonfunctional depending on their production of specific pancreatic endocrine hormones (e.g. " 09/28/2005 - "Non-functional islet cell tumor lack specificity, Bus and CT are primary examination methods, immuno-histological analysis indicates various different hormones, but lacks the presence of related clinical symptoms. " 01/01/2004 - "VHL-associated islet cell tumors are mostly hormone-inactive. " 12/01/1999 - "It is well known that an islet cell tumor can secrete multiple hormones depending on its cell type. " 12/01/1994 - "Functioning islet cell tumors (FIT) elaborate a variety of hormones, producing dramatic symptoms, while the initial presentation of non-functioning islet cell tumors (NIT) is commonly an abdominal mass or symptom complex related to invasion of adjacent structures. "
6.	Adrenocorticotropic Hormone (ACTH)FDA Link 12/01/1995 - "Role of surgery in management of adrenocorticotropic hormone-producing islet cell tumors of the pancreas." 01/01/1995 - "Adrenocorticotropic hormone (ACTH) secreting islet cell tumors of the pancreas are extremely rare. " 01/01/1994 - "No occult ACTH-producing islet cell tumor was encountered in the authors' experience or in a review of the literature." 01/01/1994 - "In addition, 53 cases of ACTH-secreting islet cell tumors in the English-language literature were reviewed. " 01/01/1994 - "To evaluate the frequency with which benign occult islet cell tumors cause ectopic adrenocorticotropic hormone (ACTH) syndrome. "
7.	AntigensIBA 01/01/1990 - "A variable number of islet cells was found to react with beta-endorphin antiserum in all 3 cases, while the reaction with antiserum against the neural tissue marker antigen, S-100, was restricted to the cases with islet-cell adenoma. " 06/07/1979 - "When beta cells were lacking in islet-cell tumors or in the pancreas of a patient with juvenile-onset diabetes, kallikrein antigen was not detectable. " 10/25/2001 - "To evaluate the efficacy of Mitf as a marker for melanoma in cytologic preparations, 81 cell blocks from 44 patients with melanoma and 37 patients with nonmelanoma malignancies (29 patients with carcinoma, 4 patients with mesotheliomas, 2 patients with lymphoma, and 2 patients with islet cell tumors) were stained with monoclonal antibodies against Mitf (clone D5), S-100 protein, and HMB-45 antigen. " 02/01/1991 - "From the results of histological and immunohistochemical studies, this was diagnosed as a malignant islet cell tumor producing multiple hormones such as insulin, glucagon, somatostatin and pancreatic polypeptide, as well as expressing the tumor-related antigens CEA and CA19-9. "
8.	Transforming Growth Factor beta (TGF-beta)IBA 11/01/1998 - "In the clinical diagnostic arena: the World Health Organization established a standard nomenclature for intraductal papillary mucinous neoplasms, mucinous cystic tumors, intraductal mucinous hyperplasias, and solid pseudopapillary tumors; focal glandular differentiation may be commonly identified within pancreatic endocrine neoplasms (islet cell tumors) while not necessarily implying an unfavorable prognosis typical of ductal adenocarcinomas; positron emission tomography scanning may be used for evaluation of early tumor response to novel chemotherapeutic regimens; helical computed tomography (CT) is the state of the art in preoperative imaging for pancreatic cancer; neoadjuvant 5-fluorouracil (5-FU)-based chemoradiation in 39 "resectable" patients provided a median survival of 19 months, actuarial 4-year survival of 19%, and improved local tumor control; gemcitabine has shown promise in alleviating tumor-related symptoms with a significantly better "clinical benefit response" than single agent 5-FU (23.8 vs. 4.8%, p = 0.0022) based on change in pain intensity, daily analgesic consumption, performance status, and weight; a significant survival advantage was demonstrated in patients treated with conventional therapies whose tumors expressed p21WAF-1, an important inhibitor of cell cycle progression and downstream molecule of p53 and TGF-beta; a p21-adenovirus (rAD-p21) gene therapy resulted in significant growth inhibition of pancreatic cancer cell lines in tissue culture, and development of a successful SCID mouse-human pancreatic adenocarcinoma xenograft model provided an animal model for preclinical trials of rAD-p21."
9.	gemcitabine FDA Link 11/01/1998 - "In the clinical diagnostic arena: the World Health Organization established a standard nomenclature for intraductal papillary mucinous neoplasms, mucinous cystic tumors, intraductal mucinous hyperplasias, and solid pseudopapillary tumors; focal glandular differentiation may be commonly identified within pancreatic endocrine neoplasms (islet cell tumors) while not necessarily implying an unfavorable prognosis typical of ductal adenocarcinomas; positron emission tomography scanning may be used for evaluation of early tumor response to novel chemotherapeutic regimens; helical computed tomography (CT) is the state of the art in preoperative imaging for pancreatic cancer; neoadjuvant 5-fluorouracil (5-FU)-based chemoradiation in 39 "resectable" patients provided a median survival of 19 months, actuarial 4-year survival of 19%, and improved local tumor control; gemcitabine has shown promise in alleviating tumor-related symptoms with a significantly better "clinical benefit response" than single agent 5-FU (23.8 vs. 4.8%, p = 0.0022) based on change in pain intensity, daily analgesic consumption, performance status, and weight; a significant survival advantage was demonstrated in patients treated with conventional therapies whose tumors expressed p21WAF-1, an important inhibitor of cell cycle progression and downstream molecule of p53 and TGF-beta; a p21-adenovirus (rAD-p21) gene therapy resulted in significant growth inhibition of pancreatic cancer cell lines in tissue culture, and development of a successful SCID mouse-human pancreatic adenocarcinoma xenograft model provided an animal model for preclinical trials of rAD-p21."
10.	Insulin-Like Growth Factor II (Somatomedin A)IBA 03/01/2014 - "PubMed searches were conducted for: "non-islet-cell tumor hypoglycemia," "NICTH," "Doege-Potter," "Doege-Potter syndrome," "high molecular weight IGF-II," and "big IGF-II." Relevant articles were reviewed in detail. " 01/01/2012 - "These findings suggested that the cause of the recurrent severe hypoglycemia was SFT production of HMW IGF-II, a mediator of non-islet cell tumor-induced hypoglycemia (NICTH)." 07/01/2009 - "We investigated the imprinting control and promoter usage for IGF2 expression to identify a mechanism for increased IGF-II production in non-islet-cell tumor hypoglycemia. " 01/01/2007 - "Severe hypoglycemia induced by IGF-II producing non-islet cell tumor." 08/01/2006 - "Clinical features of insulin-like growth factor-II producing non-islet-cell tumor hypoglycemia."

Therapies and Procedures

1.	Pancreatectomy 07/01/2013 - "Anesthetists approach in a neonate with nesidioblastoma undergoing pancreatectomy." 10/01/2002 - "All consecutive patients who underwent PD or total pancreatectomy for islet cell tumors between 1980 and 1995 were analyzed. " 10/01/2000 - "A 57-year-old woman underwent distal pancreatectomy for malignant islet cell tumor of the pancreas in 1991. " 12/01/1999 - "Liver biopsy and distal pancreatectomy were performed, and the pathological diagnosis was malignant islet cell tumor. " 01/01/1999 - "Laparoscopic distal pancreatectomy combined with spleen salvage by preservation of the splenic vessels has been described in selected patients with islet cell tumors. "
2.	Heterologous Transplantation (Xenotransplantation) 11/01/1998 - "In the clinical diagnostic arena: the World Health Organization established a standard nomenclature for intraductal papillary mucinous neoplasms, mucinous cystic tumors, intraductal mucinous hyperplasias, and solid pseudopapillary tumors; focal glandular differentiation may be commonly identified within pancreatic endocrine neoplasms (islet cell tumors) while not necessarily implying an unfavorable prognosis typical of ductal adenocarcinomas; positron emission tomography scanning may be used for evaluation of early tumor response to novel chemotherapeutic regimens; helical computed tomography (CT) is the state of the art in preoperative imaging for pancreatic cancer; neoadjuvant 5-fluorouracil (5-FU)-based chemoradiation in 39 "resectable" patients provided a median survival of 19 months, actuarial 4-year survival of 19%, and improved local tumor control; gemcitabine has shown promise in alleviating tumor-related symptoms with a significantly better "clinical benefit response" than single agent 5-FU (23.8 vs. 4.8%, p = 0.0022) based on change in pain intensity, daily analgesic consumption, performance status, and weight; a significant survival advantage was demonstrated in patients treated with conventional therapies whose tumors expressed p21WAF-1, an important inhibitor of cell cycle progression and downstream molecule of p53 and TGF-beta; a p21-adenovirus (rAD-p21) gene therapy resulted in significant growth inhibition of pancreatic cancer cell lines in tissue culture, and development of a successful SCID mouse-human pancreatic adenocarcinoma xenograft model provided an animal model for preclinical trials of rAD-p21."
3.	Radiotherapy 09/15/1987 - "This article describes three cases of advanced islet cell tumors treated effectively with radiotherapy. " 06/01/1968 - "Prolonged remission of diarrhea due to nonbeta islet cell tumor of the pancreas by radiotherapy."
4.	Laparotomy 04/01/2001 - "Laparoscopy predicts metastatic disease and spares laparotomy in selected patients with pancreatic nonfunctioning islet cell tumors." 12/01/2000 - "Operative procedures for the nonfunctioning islet cell tumors included nine pancreaticoduodenectomies, 12 distal pancreatectomies, three palliative bypasses, and four exploratory laparotomies without a resection or bypass. " 01/01/1981 - "An exploratory laparotomy revealed an islet cell tumor measuring 12 cm in diameter extending anteriorly from head of the pancreas with metastases in the liver. " 02/01/1988 - "The purpose of the present study was to evaluate prospectively the value of intraoperative ultrasound scanning (IOUS) in localizing islet cell tumors by comparing results of IOUS to those of palpation during 44 consecutive laparotomies for gastrinoma (36) or insulinoma (8). "
5.	Pancreaticoduodenectomy 10/01/2002 - "Pancreaticoduodenectomy for islet cell tumors of the head of the pancreas: long-term survival analysis." 08/01/1993 - "Pancreaticoduodenectomy with revascularization of the hepatic artery and portal vein was performed on a 17-year-old girl with giant nonfunctioning islet cell tumor of the pancreas. " 08/01/1993 - "Giant nonfunctioning islet cell tumor requiring pancreaticoduodenectomy and complete liver revascularization." 06/01/1985 - "A case is reported of a pancreatic nesidioblastoma located in two regions, treatment being by total duodenopancreatectomy with a good result at 4-year follow up review. " 06/01/1985 - "[Total duodenopancreatectomy for non-secreting pancreatic nesidioblastoma]."